Background. Patients with advanced non-small cell lung cancer (NSCLC) and high PD-L1 (>50%) expression show improved outcomes with immune checkpoint inhibitors compared to chemotherapy. We hypothesized that concurrent durvalumab and radiotherapy (RT) without concurrent chemotherapy would be safe and feasible in patient...
Steven H. Lin, S. L. Pugh, D. D. Del Valle et al.· International Journal of Rad...· 0 citations
It is suggested rigosertib normalizes and reverses RASopathy-associated HCM and other NS-associated syndromic features, supporting its development as a promising treatment for RAF1-associated HCM and, potentially, other RASopathy-dependent pathologies.
Levi Legler, K. Marchetti, Bing Xu et al.· Circulation· 0 citations
An expanded and standardized framework that harmonizes human systems vaccinology datasets using ImmPort metadata, and develops an automated pipeline to integrate experimental design, clinical metadata and serological response data from ImmPort with linked transcriptional profiling data from GEO is presented.
Jian Xing, Gisela Gabernet, Anthony Melillo et al.· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.